@article {Chris:November 2004:1743-6095:292,
	author = "Chris McMahon",
	title = "Efficacy and Safety of Daily Tadalafil in Men with Erectile Dysfunction Previously Unresponsive to On-demand Tadalafil",
	journal = "The Journal of Sexual Medicine",
	volume = "1",
	year = "November 2004",
	abstract = "Conflict of Interest. Dr. McMahon is a paid consultant and/or investigator and/or member of speakers panel for Pfizer, Bayer, GlaxoSmithKline, Eli Lilly, Icos Corp., American Medical Systems, and Johnson &amp; Johnson. ABSTRACT Objective. <P></P>To assess the efficacy and safety of daily tadalafil, a potent selective phosphodiesterase 5 inhibitor, for the treatment of erectile dysfunction (ED) in men previously unresponsive to on-demand tadalafil. Materials and Methods. <P></P>A total of 112 men with a mean age of 63 (range 21&#150;79) and moderate to severe ED of various aetiologies were treated with tadalafil, taken on a daily basis at flexible daily doses of 10 and 20 mg for 12 weeks. The three primary outcomes were changes from the pretreatment and on-demand tadalafil baseline in the erectile function domain of the International Index of Erectile Function and the proportion of yes responses to questions 2 and 3 of the Sexual Encounter Profile. Additional efficacy instruments included a Global Assessment Question administered at completion of the study. Results. <P></P>Compared with pretreatment and on-demand tadalafil baseline, daily dosed tadalafil significantly enhanced all efficacy outcome variables. Patients receiving daily tadalafil (10 mg) experienced a significant mean improvement of 12.8 and 8.2 in the International Index of Erectile Function erectile function domain score from baseline (<I>P</I> &#060; 0.001) and from on-demand tadalafil, respectively (<I>P</I> &#060; 0.001). Fifty-eight percent of intercourse attempts (Sexual Encounter Profile question 3) were successfully completed (<I>P</I> &#060; 0.001 vs. pretreatment baseline, <I>P</I> &#060; 0.001 vs. on-demand tadalafil). Improved erections at end point were reported by 69&#037; of men compared with 42&#037; of men with on-demand tadalafil. Daily tadalafil was well tolerated with headache, dyspepsia, and facial flushing as the most frequent adverse events. Conclusion. <P></P>Daily tadalafil (10/20 mg) was effective and well tolerated in this study population and is an effective salvage for previous on-demand tadalafil nonresponders.",
	pages = "292-300(9)",
	url = "http://www.ingentaconnect.com/content/bsc/jsm/2004/00000001/00000003/art00007"
	doi = "doi:10.1111/j.1743-6109.04042.x"
}